While eRegulatory (eInvestigator Site File) systems favored by study sponsors offer many advantages to sites, their adoption and use may place burdens on site personnel that can be alleviated with careful planning and collaboration between partners. Speakers in this session will share specific use cases where the use of eRegulatory has made a positive impact on clinical trials, as well as overall metrics on site adoption, user feedback from site and sponsor roles, and lessons learned and future opportunities for both study coordinators and monitors.

CEU: 1.00 ACRP

Speakers:

• Dan Knight, Associate Director of Clinical Research, Merck

• Kayla Perry, Clinical Research Associate, Merck

Watch a Sneak Peek into the Session Content